Examining the link between serum albumin levels and hepatic encephalopathy severity in chronic liver disease patients
Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver Disease in Sohag University Hospital
This study is trying to see if the level of a protein called serum albumin in the blood is related to how severe brain problems are in people with chronic liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06953921 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the correlation between serum albumin levels and the severity of hepatic encephalopathy (HE) in patients with chronic liver disease. A sample size of 100-150 patients will be evaluated to ensure adequate statistical power, with assessments including Glasgow Coma Scale scores and various laboratory investigations. The study will also consider clinical characteristics such as prior HE episodes, presence of ascites, and other complications related to chronic liver disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with confirmed chronic liver disease and diagnosed hepatic encephalopathy.
Not a fit: Patients with acute liver failure, chronic renal failure on dialysis, or active malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how serum albumin levels impact the clinical course and outcomes of hepatic encephalopathy, potentially leading to improved management strategies.
How similar studies have performed: While the correlation between serum albumin levels and hepatic encephalopathy has been explored in other studies, this specific approach focusing on a defined patient population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients aged \>18 years. * Confirmed chronic liver disease (by imaging , * liver function tests , and clinical history). * Diagnosed with hepatic encephalopathy based on clinical criteria. * Patients able to provide informed consent. Exclusion Criteria: * Patients age less than 18 years old * Acute liver failure. * Chronic renal failure on dialysis. * Pregnant women. * Patients with active malignancy.
Where this trial is running
Sohag
- Sohag university hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Kerelos L Sweha, Resident
- Email: kerolos_latief_post@med.sohag.edu.eg
- Phone: +201280416877
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.